



FINANCIAL TEAR SHEET

CORPORATE PROFILE

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

STOCK MARKET DATA

ERYP.PA (Common Stock)

Exchange	Paris (Euro)
Price	€24.15
Change (%)	▼ 0.31 (1.27%)
Volume	26,926
52 Week Low	€11.50
Market Cap	€213,076,611
Rolling EPS	-2.94
PE Ratio	0

Shares Outstanding 8,732,648

Data as of 08/23/17 5:35 p.m. ET



RECENT NEWS & EVENTS

	Date	Title
04-Aug-2017 ERYTECH Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –July 31st, 2017 (phoenix.zhtml?c=254271&p=irol-newsArticle&ID=2291993)	09/11/17	Second Quarter and Half-Year 2017 Financial Results and Business Update: Press Release: Monday, September 11, 2017 (after market)
12-Jul-2017 ERYTECH Announces Collaboration with Queen's University to Advance its Product Candidate for Rare Metabolic Disorders (phoenix.zhtml?c=254271&p=irol-newsArticle&ID=2285908)	09/12/17 3:00 p.m. CET	Second Quarter and Half-Year 2017 Financial Results and Business Update: Conference Call (phoenix.zhtml?c=254271&p=irol-EventDetails&EventId=5247800)
04-Jul-2017 ERYTECH Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –May 31st, 2017 (phoenix.zhtml?c=254271&p=irol-newsArticle&ID=2284481)	11/13/17	Third Quarter 2017 Financial Results and Business Update: Press Release: Monday, November 13, 2017 (after market)

SEC FILINGS

Filing Date Form

12/22/15	D (phoenix.zhtml?c=254271&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsa)
01/09/15	EFFECT (phoenix.zhtml?c=254271&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vc
12/29/14	F-6 (phoenix.zhtml?c=254271&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsa
11/10/14	D/A (phoenix.zhtml?c=254271&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsa